Day: January 7, 2026

Publication of offer document in respect of the takeover offer from Freudenberg to the shareholders of Nilfisk Holding

Written by Customer Service on January 7, 2026. Posted in Mergers And Acquisitions.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Publication of offer document in respect of the takeover offer from Freudenberg to the shareholders of Nilfisk Holding On 11 December 2025, Nilfisk Holding A/S (Nilfisk) published announcement no. 16/2025 regarding Nilfisk entering into an announcement agreement with Freudenberg Home and Cleaning Solutions GmbH (the Offeror), a part of the German family-owned Freudenberg group (the Offeror Group), pursuant to which the Offeror will make an all-cash voluntary recommended public takeover offer to acquire all of the issued and outstanding shares (except for treasury shares and shared held by the Offeror) in Nilfisk at a price of DKK 140 per share (the Offer). Following the announcement of the Offer, the...

Pluxee Q1 Fiscal 2026 Revenues – Robust start in the 1st quarter delivering on expectations, All Fiscal 2026 financial objectives confirmed

Written by Customer Service on January 7, 2026. Posted in Public Companies.

All Fiscal 2026 financial objectives confirmed Q1 Fiscal 2026 Revenues Issy-les-Moulineaux, France – January 7th, 2026 Robust start in the 1st quarter delivering on expectationsAll Fiscal 2026 financial objectives confirmed HighlightsSustained Employee Benefits business performance in Q1 Fiscal 2026 driven by strong new client acquisition and healthy net retention Total Revenues up +9.0% organically, reaching €308m Operating revenue up +9.1% organically to €268m, supported by a strong trajectory in Employee Benefits delivering +11.6% organic growth Float revenue standing at €40m, up +8.5% organically Continued execution of the M&A roadmap with the closing of Skipr in Belgium and France, and ProEves in India, alongside a solid and diversified pipeline Pluxee confirms all its financial objectives for Fiscal 20261 amid an evolving...

Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences

Written by Customer Service on January 7, 2026. Posted in Public Companies.

Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences Halle (Saale) / Munich, Germany, January 7, 2026 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences: 1x1s around J.P. Morgan Healthcare Conference San Francisco, USADate: January 12-14, 2026To meet the team contact: IR@vivoryon.com UBS European Healthcare Conference London, UKDate: March 3-4, 2026 World Congress of Nephrology (WCN)Yokohama, JapanDate: March 28-31, 2026Link to conference: https://www.theisn.org/wcn/ ### About Vivoryon Therapeutics N.V.Vivoryon is a clinical stage...

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM – NTX-253 for Schizophrenia

Written by Customer Service on January 7, 2026. Posted in Public Companies.

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253. NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NTX-253 in healthy volunteers. “The progression of NTX-253 into clinical studies represents an important milestone for both Neurosterix and Addex,” said Tim Dyer, Chief Executive...

Technip Energies awarded two large contracts by BPCL for new units at Bina and Mumbai refineries in India

Written by Customer Service on January 7, 2026. Posted in Public Companies.

Technip Energies – BPCLTechnip Energies awarded two large contracts by BPCL for new units at Bina and Mumbai refineries in IndiaTechnip Energies (PARIS:TE) has been awarded two large(1) contracts by Bharat Petroleum Corporation Limited (BPCL) for key projects at its Bina refinery in Madhya Pradesh and Mumbai refinery in Maharashtra, India. The first contract covers Engineering, Procurement, Construction and Commissioning (EPCC) for new polypropylene and Butene-1 units at the Bina refinery in Madhya Pradesh. The units will produce 550 KTPA(2) of polypropylene and 50 KTPA of Butene-1, essential building blocks for widely used products such as packaging materials, pipes and automotive components. This contract is part of BPCL’s Bina Petchem and Refinery Expansion Project, encompassing refinery capacity increase as well as...

Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections

Written by Customer Service on January 7, 2026. Posted in Public Companies.

Allschwil, Switzerland, January 07, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, today announced an agreement with Prokaryotics Inc., a privately held US-based biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs. The collaboration aims to jointly develop a first-in-class broad-spectrum antifungal for the treatment of severe invasive infections. The collaboration is focused on a program of antifungal molecules with a novel mode of action, addressing the critical unmet need of patients with invasive infections caused by strains of Candida, Aspergillus, and rare molds. The joint efforts aim to deliver a clinical candidate, which will then be further progressed...

Lerøy Seafood Group ASA: Trading update Q4 2025

Written by Customer Service on January 7, 2026. Posted in Earnings Releases And Operating Results.

HARVEST VOLUMES OF SALMON AND TROUT Total harvest volume of salmon and trout for Q4 2025 was 49,300 GWT, compared to 56,800 GWT in Q4 2024. For the full year 2025, harvested volume of salmon and trout was 195,600 GWT compared to 171,200 GWT in 2024. These figures exclude harvest volumes from Scottish Seafarms. Harvest volumes by region/company for Q4 2025 (Q4 2024), measured in 1,000 GWT: Lerøy Aurora: 16.4 (15.4) Lerøy Midt: 16.2 (22.6) Lerøy Sjøtroll: 16.8 of which 7.9 was trout (18.8 of which 8.2 was trout) CATCH VOLUMES OF WILDFISH Total wild catch volumes in Lerøy Havfisk, measured in 1,000 tonnes: Q4 2025: 7.6 of which 2.7 of cod Q4 2024: 9.8 of which 3.1 of cod The catch volume for 2025 was 57,700 tonnes compared to 65,000 tonnes in 2024. The complete Q4 2025 report will be released on 24 February at 06:30 CET. Queries may be addressed...

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Written by Customer Service on January 7, 2026. Posted in Public Companies.

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 2,212,000 shares of its common stock at a public offering price per share of $260.00. The gross proceeds from the offering are expected to be approximately $575 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis. All shares in the offering are being offered by Praxis. In addition, Praxis has granted the underwriters a 30-day option to purchase up to 331,800 additional shares of common stock at the public offering...

Soren Acquisition Corp. Announces the Pricing of $220,000,000 Initial Public Offering

Written by Customer Service on January 7, 2026. Posted in Public Companies.

Miami, FL, Jan. 06, 2026 (GLOBE NEWSWIRE) — Soren Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 22,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Stock Market LLC (“Nasdaq”) and begin trading tomorrow, January 7, 2026, under the ticker symbol “SORNU.” Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq...

Faraday Future Announces Stockholders’ Day Save the Date for January 7, 2026, in Las Vegas, NV to Coincide with the Annual CES

Written by Customer Service on January 7, 2026. Posted in Public Companies.

The program is intended to provide stockholders with the latest development progress, business updates, and strategic insights regarding both the FF and FX brands. A livestream of the event will be available here: https://www.ff.com/us/2026-CES/LAS VEGAS, Jan. 06, 2026 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or “Company”), a California-based global shared intelligent electric mobility ecosystem company, today announced that on January 7, 2026, coinciding with CES, Faraday Future will host its Stockholders’ Day, a key annual event dedicated to transparency, execution updates, and long-term value creation. This event will be livestreamed globally, allowing stockholders and others to join in real time as FFAI leadership shares strategic insights across Faraday Future (FF)...

Day: January 7, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals